Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Padcev (enfortumab vedotin-ejfv)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Astellas, Pfizer

Drug class:

Microtubule inhibitor, Nectin-4-targeted antibody-drug conjugate

Related drugs:

‹

ado-trastuzumab emtansine (97)

eribulin mesylate (47)

brentuximab vedotin (29)

disitamab vedotin (27)

mirvetuximab soravtansine-gynx (16)

cabazitaxel (12)

ixabepilone (6)

LR004-VC-MMAE (5)

PF-06804103 (4)

PF-08046048 (4)

PF-08046047 (4)

belantamab mafodotin-blmf (3)

polatuzumab vedotin-piiq (3)

RGX-019-MMAE (3)

BAY 94-9343 (3)

IMAB027-vcMMAE (2)

PF-06650808 (2)

MF-TTZ-MMAE (1)

PF-06263507 (1)

PF-08046054 (1)

tisotumab vedotin-tftv (1)

estramustine (0)

Nectin-4 ADC (0)

vintafolide (0)

HuMax-AXL-ADC (0)

mebendazole (0)

›

No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: A1 - Approval enfortumab vedotin-ejfv Sensitive : A1	enfortumab vedotin-ejfv Sensitive: A1 - Approval enfortumab vedotin-ejfv Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	pembrolizumab + enfortumab vedotin-ejfv Sensitive: A1 - Approval pembrolizumab + enfortumab vedotin-ejfv Sensitive : A1	pembrolizumab + enfortumab vedotin-ejfv Sensitive: A1 - Approval pembrolizumab + enfortumab vedotin-ejfv Sensitive : A1
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	enfortumab vedotin-ejfv Sensitive: A2 - Guideline enfortumab vedotin-ejfv Sensitive : A2	enfortumab vedotin-ejfv Sensitive: A2 - Guideline enfortumab vedotin-ejfv Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	pembrolizumab + enfortumab vedotin-ejfv Sensitive: A2 - Guideline pembrolizumab + enfortumab vedotin-ejfv Sensitive : A2	pembrolizumab + enfortumab vedotin-ejfv Sensitive: A2 - Guideline pembrolizumab + enfortumab vedotin-ejfv Sensitive : A2
NECTIN4 expression	Urothelial Cancer	NECTIN4 expression	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: C2 – Inclusion Criteria enfortumab vedotin-ejfv Sensitive : C2	enfortumab vedotin-ejfv Sensitive: C2 – Inclusion Criteria enfortumab vedotin-ejfv Sensitive : C2
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	enfortumab vedotin-ejfv Resistant: C3 – Early Trials enfortumab vedotin-ejfv Resistant : C3	enfortumab vedotin-ejfv Resistant: C3 – Early Trials enfortumab vedotin-ejfv Resistant : C3
CDKN2B mutation	Urothelial Cancer	CDKN2B mutation	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3
TP53 mutation	Urothelial Cancer	TP53 mutation	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3
TMB-H	Urothelial Cancer	TMB-H	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	pembrolizumab + enfortumab vedotin-ejfv Sensitive: C3 – Early Trials pembrolizumab + enfortumab vedotin-ejfv Sensitive : C3	pembrolizumab + enfortumab vedotin-ejfv Sensitive: C3 – Early Trials pembrolizumab + enfortumab vedotin-ejfv Sensitive : C3
PD-L1 underexpression	Urothelial Cancer	PD-L1 underexpression	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3
KDM6A mutation	Urothelial Cancer	KDM6A mutation	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3
HER-2 mutation	Urothelial Cancer	HER-2 mutation	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3
NECTIN4 underexpression	Urothelial Cancer	NECTIN4 underexpression	Urothelial Cancer	enfortumab vedotin-ejfv Resistant: D – Preclinical enfortumab vedotin-ejfv Resistant : D	enfortumab vedotin-ejfv Resistant: D – Preclinical enfortumab vedotin-ejfv Resistant : D